Impact of CDK4/6 inhibitors on health-related quality of life outcomes in patients with metastatic breast cancer: A systematic review and meta-analysis
Treatment with CDK4/6is was not generally associated with worsening HRQoL among patients with MBC, except for the symptom-related, patient-reported measures of diarrhea and upset by hair loss. Understanding HRQoL impacts can help support health care decisions and treatment using CDK4/6is for patients with MBC.
Authors
- Quang A. Le (ORCID: https://orcid.org/0000-0002-4968-9334)
- Elaine Chiang
- Takako Kiener (ORCID: https://orcid.org/0009-0008-2472-7227)
- Kevin H. Li
Institutions
- Health Economics and Outcomes Research (United Kingdom) (GB)
- Western University of Health Sciences (US)
Publication Details
- Journal
- Journal of Managed Care & Specialty Pharmacy
- Published
- 2025-11-26
- DOI
- https://doi.org/10.18553/jmcp.2025.31.12.1285
- Citations
- 1
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.52